- ESSENCE trial data presented at AASLD 2025 shows semaglutide 2.4 mg benefits liver health in MASH patients.
- The trial evaluated 800 patients over 72 weeks, showing improvements in liver injury and scarring.
- Semaglutide 2.4 mg showed efficacy across various demographics, including age, gender, and ethnicity.
- Part 2 of the ESSENCE trial will continue with results expected in 2029.
ESSENCE Trial Findings
Novo Nordisk presented data from the ESSENCE trial at the AASLD 2025 meeting, highlighting the effects of semaglutide 2.4 mg on liver health in patients with metabolic dysfunction-associated steatohepatitis (MASH) and liver scarring. The trial involved 800 randomized patients over 72 weeks, showing that semaglutide 2.4 mg improved liver injury and scarring, even at low weight loss levels.
Demographic Insights
The trial's secondary analysis revealed that semaglutide 2.4 mg was effective across various demographics, including different ages, genders, races, and ethnicities. The treatment showed a significant resolution of liver injury and improvement in liver scarring compared to placebo.
Future Research
Part 2 of the ESSENCE trial is ongoing, with results expected in 2029. This phase aims to demonstrate the long-term effects of semaglutide 2.4 mg on reducing liver-related clinical events in adults with MASH and moderate-to-advanced liver fibrosis.
About MASH
MASH is a progressive liver disease affecting over 250 million people worldwide, often linked with obesity and type 2 diabetes. It can lead to severe liver conditions if not managed properly. The ESSENCE trial's findings provide new insights into managing MASH, emphasizing the potential of semaglutide 2.4 mg as a treatment option.
